Annovis

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease See more here

Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update See more here

Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson's disease See more here

Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegenerative Diseases With this Recent Filing, the Company Seeks Protection for Buntanetap to Treat Infection-Dependent Neurological…

Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update See more here

Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap See more here

Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson's Disease See more here

Annovis Bio Enhances Leadership Team with Two Senior Appointments Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory Operations Company Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & Development See more here

Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401 See more here

Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases See more here